Evolution of Clinical Trials in Inflammatory Bowel Diseases
Purpose of Review
Since the first clinical trial of cortisone in ulcerative colitis in 1955, remarkable progress has been made in the design and conduct of clinical trials in inflammatory bowel diseases (IBD). In this review article, we will discuss evolution of clinical trials in IBD over the last 3–5 years.
Recognizing limitations intrinsic to clinical disease activity indices in IBD, regulatory authorities have recommended evaluating co-primary endpoints of patient-reported outcomes and endoscopic disease activity in clinical trials. Biomarker-enriched trial enrolment and central endoscopy reading have emerged as critical events in trial recruitment and outcome assessment and have driven placebo response rates down. While trials of novel biologic therapies and advanced small molecules continue at an accelerated pace, pragmatic comparative efficacy trials of treatment strategy aimed at optimizing current therapies (such as early combined immunosuppression [REACT], tight disease control [CALM], therapeutic drug monitoring [TAXIT, TAILORIX]) have directly informed clinical practice. With emphasis on value-based care and population health management, multi-pronged remote monitoring, self-management, and telemedicine approaches in the era of smartphones have re-emerged with promise. Non-conventional therapies such as fecal microbiota transplantation, though still experimental, have provided insight into disease pathogenesis and offered hope for microbial manipulation strategies for treating these complex diseases.
Clinical trials have rapidly evolved over the last 5 years not only focusing on novel therapies but also optimizing existing treatment approaches and population health management. Over the next decade, these trials will continue to advance the field, and be readily translatable into clinical practice.
KeywordsComparative effectiveness Pragmatic trials Crohn’s disease Strategy
Compliance with Ethical Standards
Conflict of Interest
Siddhartha Singh is supported by the American College of Gastroenterology Junior Faculty Development Award and Crohn’s and Colitis Foundation Career Development Award. Dr. Singh has received research grants from Pfizer and AbbVie and has received consulting fees from AbbVie and AMAG Pharmaceuticals.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389:1699–709.CrossRefPubMedGoogle Scholar
- 9.Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–75.CrossRefPubMedGoogle Scholar
- 11.•• Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386:1825–34. This pivotal cluster-randomized trial represents a new type of pragmatic clinical trial evaluating early algorithmic treatment escalation in patients with Crohn’s disease. CrossRefPubMedGoogle Scholar
- 12.•• Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779–89. This pivotal strategy trial presents for the first time evidence that treatment escalated based on biomarkers and/or symptoms is superior to treatment based only on symptoms. CrossRefPubMedGoogle Scholar
- 13.• Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320–9.e3. This trial demonstrated that, after initial optimization of infliximab trough levels in patients on maintenance therapy, routine, repeated infliximab trough concentration-guided dosing is not superior to usual care. CrossRefPubMedGoogle Scholar
- 14.• D'Haens G, Vermeire S, Lambrecht G, et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease. Gastroenterology. 2018;154:1343–51. e1 In this small randomized trial of patients with active CD, investigators observed that increasing infliximab dose based on a combination of symptoms, biomarkers, and serum drug concentrations is not superior to increasing dose based on symptoms alone, in achieving corticosteroid-free clinical remission. CrossRefPubMedGoogle Scholar
- 15.•• de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390:959–68. This pragmatic trial provides solid evidence supporting a comprehensive telehealth program comprising remote monitoring and self-management for improving population health management in patients with IBD. CrossRefPubMedGoogle Scholar
- 16.• Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218–28. In this trial, investigators demonstrated that intensive-dosing, multidonor, fecal microbiota transplantation induces clinical remission and endoscopic improvement in patients with active ulcerative colitis and is associated with distinct microbial changes that relate to outcome. CrossRefPubMedGoogle Scholar
- 19.Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35:231–5.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Ma C, Hussein IM, Al-Abbar YJ, et al. Heterogeneity in definitions of efficacy and safety endpoints for clinical trials of Crohn’s disease: a systematic review for development of a core outcome set. Clin Gastroenterol Hepatol. 2018.Google Scholar
- 27.•• de Jong MJ, Huibregtse R, Masclee AAM, Jonkers DMAE, Pierik MJ. Patient-reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: a systematic review. Clin Gastroenterol Hepatol. 2018;16:648–663 e3. This comprehensive systematic review provides a detailed evaluation of all available patient-reported outcomes measures and their relevance to clinical trials and clinical practice in IBD. CrossRefPubMedGoogle Scholar
- 32.Khanna R, Nelson SA, Feagan BG, et al. Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database Syst Rev 2016; CD010642.Google Scholar
- 42.Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919–27.CrossRefPubMedGoogle Scholar
- 43.Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15:1580–1588 e3.CrossRefPubMedGoogle Scholar
- 44.Papamichael K, Vajravelu RK, Vaughn BP, Osterman MT, Cheifetz AS. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis. 2018;12:804–10.CrossRefPubMedGoogle Scholar
- 47.Regueiro M, Click B, Anderson A, Shrank W, Kogan J, McAnallen S, Szigethy E Reduced unplanned care and disease activity and increased quality of life after patient enrollment in an inflammatory bowel disease medical home. Clin Gastroenterol Hepatol 2018.Google Scholar